NFKB1 and ovarian carcinoma: In fact, using the TAK1 inhibitor (5Z) -7-Oxozeaenol, as well as gain- and loss-of-function genetic modifications of TAK1, we have provided strong evidences to support that TAK1 is required for NF-κB activation in ovarian cancer.